Providence Medical Technology closed a US $10.5MM debt agreement that will support distribution of cervical fusion technology in U.S. and ex-U.S. markets.
Vericel entered into a license agreement whereby Innovative Cellular Therapeutics will obtain exclusive rights to develop and distribute Carticel® and MACI® in Southeast Asia.
Conventus Orthopaedics completed a US $20MM equity financing. Funds will support commercialization of proximal humerus fracture repair technology and the development of the Conventus Cageâ„¢ intramedullary implant.
Episurf Medical was granted a U.S. patent covering its surgical drill guide with depth adjustment functionality, part of the Episealer® joint implant system.
Carmell Therapeutics will launch a Phase III clinical study for Bone Healing Accelerant, its first Plasma-based Bioactive Material product/indication, designed to treat fractures.
Studies indicate that, at 5 years, the activ-L® Artificial Disc from Aesculap Implant Systems had a protective effect on the progression of degenerative disc disease at adjacent levels in 91.2% of patients.Â